trending Market Intelligence /marketintelligence/en/news-insights/trending/cIWFxY9LR_p4zN5511CcKg2 content esgSubNav
In This List

Genocea granted extension to regain compliance with Nasdaq listing requirement

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Genocea granted extension to regain compliance with Nasdaq listing requirement

Genocea Biosciences Inc. was granted an additional 180 calendar days, or until June 11, 2019, by Nasdaq to regain compliance with the exchange's $1 minimum bid price listing requirement.

Previously, the Cambridge, Mass.-based biopharmaceutical company was given until Dec. 12 to regain compliance for continued listing on Nasdaq.

Genocea became eligible for the extension period after it determined it will not be in compliance by Dec. 12 and submitted an application to transfer its securities from listing on the Nasdaq Global Market to the Nasdaq Capital Market.

As a result, Genocea's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market at business open on Dec. 17. The company's common stock will continue to trade under the symbol GNCA.

Genocea Biosciences develops vaccines and immunotherapies to treat infectious diseases and cancer.